CatalystWireBeta

Ottawa Heart (UOHI) Study Results Published in JHI

In brief · summary, not quotable

Journal of Hospital Infection publishes study showing Steriwave nasal photodisinfection reduced harvest site infections by 52.8% in CABG procedures.

  • Conduit harvest surgical site infections reduction 3.6% to 1.7%
  • Protocol compliance increase 35.4% to 93.3%
  • Relative reduction in conduit harvest site infections 52.8%
  • CABG procedures analyzed 2,172
  • Total surgical site infections reduction 9.1% to 5.9%
Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your OBI notes

Journal of Hospital Infection Publishes Study Linking Steriwave® Implementation to 52.8% Relative Reduction in Conduit Harvest Site Infections

Interrupted time series of 2,172 CABG procedures reports nasal decolonisation compliance rising from 35.4% to 93.3% and conduit harvest surgical site infections falling from 3.6% to 1.7%.

Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies to prevent hospital infections, announces the publication of an independent, peer-reviewed clinical investigation in the Journal of Hospital Infection (“JHI”) conducted by researchers and clinicians at the University of Ottawa Heart Institute (“UOHI”).[1]

Following preliminary presentations at the Canadian Cardiovascular Congress (“CCC 2026”), the peer-reviewed publication provides complete 32-month interrupted time series data across 2,172 consecutive coronary artery bypass graft (“CABG”) procedures. The findings report that transitioning from multi-day outpatient administered topical antibiotic regimens to nurse-administered, point-of-care Steriwave® nasal photodisinfection was associated with 93.3% protocol adherence and a reduction in conduit harvest surgical site infections (“CHSSIs”) from 3.6% to 1.7%.

Key Publication Highlights

Peer-Reviewed Publication: The Journal of Hospital Infection published 32-month interrupted time series outcomes from UOHI evaluating universal point-of-care Steriwave nasal photodisinfection across 2,172 consecutive CABG procedures, comprising a 24-month baseline mupirocin era (n=1,678) and an 8-month Steriwave intervention era (n=494).

52.8% Relative Reduction in Conduit Harvest Site Infections: Implementation of Steriwave was associated with a reduction in conduit harvest surgical site infections from 3.6% in the mupirocin era to 1.7% in the Steriwave era. In the interrupted time series model, the reduction was statistically significant (RR 0.20, 95% CI 0.05–0.72; p=0.014). In a sensitivity analysis excluding the June 2025 transition month, CHSSI remained lower but the difference was no longer statistically significant.

93.3% Protocol Compliance: Transitioning to a nurse-led, point-of-care protocol increased overall perioperative decolonisation compliance from 35.4% under outpatient topical mupirocin to 93.3% with Steriwave. Among urgent, non-elective cardiac patients, those who cannot complete multi-day pre-admission regimens, compliance rose from 17.5% to over 93%.

Fewer Total Surgical Site Infections (secondary outcome): Across the entire cohort, total surgical site infections declined from 9.1% before to 5.9% after Steriwave implementation; this secondary outcome did not reach statistical significance. Sternal wound outcomes were directionally consistent but not statistically significant.

These results reflect a before-and-after comparison with mupirocin as used in routine practice at UOHI and are not a randomised comparison.

  • Fraser D. Rubens, MD, MSc, FRCSC, FACS, lead author, Professor of Cardiac Surgery at the University of Ottawa and Cardiac Surgeon at the University of Ottawa Heart Institute, stated:

"Surgical site infections following coronary bypass carry devastating physical and financial tolls. Our study found that moving away from complex, multi-day patient-administered antibiotic regimens to a nurse-delivered, point-of-care photodisinfection treatment substantially reduced the compliance barrier. Achieving 93.3% compliance across both elective and emergency cases was accompanied by a significant drop in harvest conduit wound infections, underscoring the operational value of universal point-of-care decolonisation."

Carolyn Cross, Chief Executive Officer of Ondine Biomedical, commented:

"We congratulate Dr. Rubens and the entire clinical research team at the University of Ottawa Heart Institute on this new publication in the Journal of Hospital Infection. Real-world clinical compliance is often the Achilles' heel of infection prevention, particularly in high-acuity cardiac surgery where urgent cases cannot accommodate a multi-day antibiotic-based decolonisation regimen.”

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company focused on the development of light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those associated with multidrug-resistant organisms. Ondine's lead photodisinfection product is authorised for nasal decolonisation in Canada, the UK and certain other international markets, where it is marketed as Steriwave®. The Company also has a pipeline of additional photodisinfection products in various stages of development for applications including chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

About Steriwave® and its Mode of Action

Steriwave nasal photodisinfection is a light-activated antimicrobial therapy designed to rapidly eliminate potentially pathogenic microorganisms in the nose, a major reservoir from which pathogens can spread to cause infection. Applied by a healthcare professional, the treatment uses a proprietary photosensitising agent activated by red light to produce a rapid antimicrobial effect through oxidative mechanisms. Because the mechanisms act through non-antibiotic oxidative pathways, Steriwave has a low potential for the development of microbial resistance.

Regulatory Status and Clinical Data Disclaimer

Regulatory approvals, clearances and authorisations vary by jurisdiction, and indications, claims and availability may differ between markets. Ondine's photodisinfection products, including its nasal photodisinfection technology, are not approved or cleared by the U.S. Food and Drug Administration ("FDA") and are not commercially available in the United States, where they are limited by federal law to investigational use only. Their safety and effectiveness have not been established by the FDA, and any future U.S. marketing would be subject to FDA review and approval. No statement in this announcement should be interpreted as representing approval, clearance, authorisation or commercial availability in any jurisdiction, or for any use, where such status has not been granted.

References to clinical outcomes in this announcement should be interpreted in the context of the specific studies, real-world evaluations, endpoints and patient populations described, and do not imply regulatory approval for any particular indication or jurisdiction.

References

Rubens, F. D., et al. (2026). Nasal Photodisinfection and Surgical Site Infection Following Coronary Bypass Surgery: An Interrupted Time Series Analysis. Journal of Hospital Infection. DOI: 10.1016/j.jhin.2026.10.017.

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note